TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the modern approach to GVHD prevention, GVHD rates have reduced markedly.
Epistemonikos ID: 0c2177d80aaf272cd3145aa47b1270354d5480cc
First added on: Dec 25, 2025